

Cora N Sternberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9066536/publications.pdf>

Version: 2024-02-01

350
papers

45,583
citations

5876

81
h-index

1895

208
g-index

356
all docs

356
docs citations

356
times ranked

26376
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	1.1	4
2	Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. <i>European Urology</i> , 2022, 81, 50-61.	0.9	43
3	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 430-439.	2.9	15
4	Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3182-3192.	1.1	4
5	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. <i>European Journal of Cancer</i> , 2022, 163, 55-65.	1.3	5
6	Clinical Trials Corner Issue 8(1). <i>Bladder Cancer</i> , 2022, , 1-3.	0.2	0
7	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.	0.8	0
8	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	0.8	7
9	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of ²²⁵ Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 77-77.	0.8	1
10	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	2.0	5
11	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS581-TPS581.	0.8	4
12	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS578-TPS578.	0.8	1
13	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.. <i>Journal of Clinical Oncology</i> , 2022, 40, 512-512.	0.8	2
14	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
15	Quantitative assessment of PSMA imaging before and after ¹⁷⁷ Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	0.8	0
16	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- ²²⁵ Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS216-TPS216.	0.8	2
17	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, 434-434.	0.8	26
18	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142.	13.9	341

#	ARTICLE	IF	CITATIONS
19	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. <i>Molecular Oncology</i> , 2022, 16, 2384-2395.	2.1	5
20	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	5.8	3
21	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
22	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. <i>Future Oncology</i> , 2022, 18, 2361-2371.	1.1	4
23	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
24	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
25	Clinical Trials Corner Issue 8(2). <i>Bladder Cancer</i> , 2022, , 1-3.	0.2	0
26	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
27	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	6.0	75
28	Abstract 6317: Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial. <i>Cancer Research</i> , 2022, 82, 6317-6317.	0.4	0
29	Phase I/II study of ²²⁵ Ac-J591 plus ¹⁷⁷ Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5100-TPS5100.	0.8	1
30	A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5082-5082.	0.8	3
31	Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5078-5078.	0.8	10
32	Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5056-5056.	0.8	4
33	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	1.6	4
34	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , 2021, 14, 100944.	1.7	10
35	A phase I/II dose-escalation study of fractionated and multiple dose ²²⁵ Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS188-TPS188.	0.8	2
36	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 13-13.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 140-140.	0.8	0
38	Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.. Journal of Clinical Oncology, 2021, 39, 459-459.	0.8	0
39	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. Journal of Clinical Oncology, 2021, 39, 84-84.	0.8	1
40	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.. Journal of Clinical Oncology, 2021, 39, 438-438.	0.8	13
41	An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).. Journal of Clinical Oncology, 2021, 39, 429-429.	0.8	0
42	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2021, 39, 120-120.	0.8	1
43	Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2021, 39, 101-101.	0.8	3
44	Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).. Journal of Clinical Oncology, 2021, 39, 94-94.	0.8	3
45	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 158-158.	0.8	1
46	Clinical Trials Corner Issue 7(1). Bladder Cancer, 2021, 7, 103-106.	0.2	0
47	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	0.9	39
48	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. Japanese Journal of Clinical Oncology, 2021, 51, 1287-1297.	0.6	1
49	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529.	0.9	30
50	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
51	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. Journal of Clinical Oncology, 2021, 39, TPS5095-TPS5095.	0.8	0
52	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.. Journal of Clinical Oncology, 2021, 39, 4527-4527.	0.8	11
53	Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. Journal of Clinical Oncology, 2021, 39, 5040-5040.	0.8	0
54	Clinical Trials Corner Issue 7(2). Bladder Cancer, 2021, 7, 257-260.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. Journal of Clinical Oncology, 2021, 39, 5055-5055.	0.8	0
56	Phase I study of ²²⁵ Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5015-5015.	0.8	24
57	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	0.8	83
58	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	0.8	108
59	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	3.4	31
60	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2021, 5, 1200-1220.	1.5	17
61	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	6.3	167
62	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist, 2021, 26, 1026-1034.	1.9	8
63	Clinical Trials Corner Issue 7(3). Bladder Cancer, 2021, 7, 381-384.	0.2	0
64	Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. Journal of Urology, 2021, 206, 240-251.	0.2	7
65	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of Clinical Oncology, 2021, 39, 2474-2485.	0.8	250
66	Validation of a Circulating Tumor <i>DNA</i> -Based <i>Next-Generation</i> Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Oncologist, 2021, 26, e1971-e1981.	1.9	11
67	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	2
68	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European Urology, 2021, 80, 497-506.	0.9	16
69	Response to Rucaparib in <i>BRCA</i> -Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical Cancer Research, 2021, 27, 6677-6686.	3.2	12
70	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	1.7	3
71	Clinical Trials Corner Issue 7(4). Bladder Cancer, 2021, , 1-4.	0.2	0
72	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer, 2021, 159, 237-246.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65
74	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020, 3, 671-679.	2.6	11
75	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	2.6	41
76	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020, 3, 176-182.	2.6	19
77	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	0.9	91
78	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.2	2
79	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
80	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>JAMA Oncology</i> , 2020, 6, 217.	3.4	18
81	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. <i>European Journal of Cancer</i> , 2020, 138, 202-211.	1.3	19
82	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. <i>European Urology</i> , 2020, 78, 847-853.	0.9	9
83	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e1-934.e9.	0.8	2
84	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
85	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020, 11, 6195.	5.8	21
86	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
87	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
88	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
89	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	5.1	35
90	Clinical Trials Corner. <i>Bladder Cancer</i> , 2020, 6, 93-95.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Clinical Trials Corner. Bladder Cancer, 2020, 6, 219-221.	0.2	0
92	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 680-688.	2.0	20
93	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2197-2206.	13.9	253
94	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer Treatment Reviews, 2020, 88, 102057.	3.4	28
95	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
96	<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	1.5	138
97	Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2020, 38, 5515-5515.	0.8	17
98	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. Journal of Clinical Oncology, 2020, 38, 5559-5559.	0.8	2
99	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. Journal of Clinical Oncology, 2020, 38, LBA1-LBA1.	0.8	64
100	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. Journal of Clinical Oncology, 2020, 38, 16-16.	0.8	3
101	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	13
102	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 32-32.	0.8	2
103	FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.. Journal of Clinical Oncology, 2020, 38, 489-489.	0.8	32
104	FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.. Journal of Clinical Oncology, 2020, 38, TPS590-TPS590.	0.8	7
105	Cell cycle inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS606-TPS606.	0.8	1
106	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 5569-5569.	0.8	1
107	Cell cycle inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS5096-TPS5096.	0.8	0
108	Clinical Trials Corner Issue 6(4). Bladder Cancer, 2020, 6, 553-556.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 50-50.	0.8	0
110	Serial circulating tumor DNA (ctDNA) measurement to predict progression in patients (pts) with advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 558-558.	0.8	0
111	Clinical Trials Corner Issue 6(3). <i>Bladder Cancer</i> , 2020, 6, 395-398.	0.2	0
112	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	1.3	70
113	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	0.9	15
114	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	13.9	403
115	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
116	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	3.4	50
117	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	0.9	117
118	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1437-1457.	1.1	16
119	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. <i>European Urology Oncology</i> , 2019, 2, 677-684.	2.6	22
120	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	3.2	147
121	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
122	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	5.1	90
123	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
124	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019, 5, 83-84.	0.2	0
125	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019, 5, 185-187.	0.2	0
126	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019, 5, 309-311.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	2.6	11
128	Somatic and germline sequencing in genitourinary oncology. <i>Current Opinion in Urology</i> , 2019, 29, 315-318.	0.9	2
129	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
130	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	15
131	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 95-105.	1.2	19
132	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	1.6	11
133	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	0.9	333
134	Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4519-4519.	0.8	2
135	Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 253-253.	0.8	3
136	Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 256-256.	0.8	10
137	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS495-TPS495.	0.8	3
138	A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 185-185.	0.8	1
139	The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 183-183.	0.8	0
140	External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5022-5022.	0.8	0
141	Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5073-5073.	0.8	0
142	Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16077-e16077.	0.8	1
143	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16017-e16017.	0.8	0
144	Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5026-5026.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
146	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013.	3.2	48
147	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 25-37.	3.4	37
148	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
149	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018, 4, 937-945.	1.6	7
150	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	0.8	97
151	Clinical Trials Corner. <i>Bladder Cancer</i> , 2018, 4, 447-449.	0.2	0
152	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
153	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 944.	3.4	86
154	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	0.9	77
155	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2465-2474.	13.9	782
156	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	0.9	30
157	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	13.9	2,677
158	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. <i>Oncologist</i> , 2017, 22, 667-679.	1.9	62
159	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	0.9	56
160	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , 2017, 390, 2266-2277.	6.3	153
161	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 168-171.	0.9	48
162	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017, 71, 151-154.	0.9	306

#	ARTICLE	IF	CITATIONS
163	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	3.4	33
164	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
165	Clinical Trials Corner. <i>Bladder Cancer</i> , 2016, 2, 469-471.	0.2	0
166	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 480-487.	1.6	15
167	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
168	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	2.0	10
169	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	0.8	202
170	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016, 48, 1490-1499.	9.4	250
171	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
172	Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. <i>European Urology</i> , 2016, 69, 1155-1156.	0.9	2
173	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 675-683.	0.9	70
174	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
175	A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. <i>Annals of Nuclear Medicine</i> , 2016, 30, 163-168.	1.2	32
176	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 545-557.	6.3	878
177	Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3325.	2.0	44
178	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3â€“pT4 or N+ MO urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86.	5.1	323
179	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , 2015, 115, 41-49.	1.3	13
180	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	5.1	1,100

#	ARTICLE	IF	CITATIONS
181	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
182	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	2.0	23
183	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 509-521.	5.1	174
184	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
185	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 417-425.	5.1	137
186	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	1.9	23
187	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
188	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	1.0	47
189	Hormonal therapy and chemotherapy in hormone-naïve and castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2015, 4, 355-64.	0.6	19
190	Pharmacotherapy options for advanced renal cell carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 643-652.	0.5	0
191	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014, 113, E137-43.	1.3	31
192	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014, 32, 4172-4173.	0.8	0
193	Reply to S. Barni et al and M. Sun et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3783-3784.	0.8	1
194	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 262-269.	0.9	9
195	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor- κ B Ligand Inhibitors in Patients with Advanced Prostate Cancer. <i>European Urology</i> , 2014, 65, 278-286.	0.9	41
196	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
197	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1412-1418.	0.8	381
198	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , The, 2014, 15, 1147-1156.	5.1	181

#	ARTICLE	IF	CITATIONS
199	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology</i> , The, 2014, 15, 1263-1268.	5.1	46
200	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	13.9	2,456
201	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	0.9	27
202	Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2014, 66, 55-56.	0.9	14
203	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
204	Reducing the burden of bone metastases. <i>Supportive Care in Cancer</i> , 2013, 21, 1773-1783.	1.0	24
205	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	13.9	1,648
206	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma in Noadjuvant and Adjuvant Settings. <i>European Urology</i> , 2013, 63, 58-66.	0.9	151
207	Randomized phase III study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013, 111, 44-52.	1.3	67
208	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	0.9	104
209	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	0.8	388
210	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1729-1737.	3.0	150
211	Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX3501). <i>Cancer</i> , 2013, 119, 3610-3618.	2.0	51
212	An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. <i>Frontiers in Oncology</i> , 2012, 2, 175.	1.3	2
213	Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 493-497.	0.6	6
214	Metastatic bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 304-309.	0.5	9
215	Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 851-859.	1.0	24
216	Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. <i>Journal of the National Cancer Institute</i> , 2012, 104, 93-113.	3.0	197

#	ARTICLE	IF	CITATIONS
217	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 1187-1197.	13.9	3,847
218	Clinical and pharmacokinetic evaluation of satraplatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 103-111.	1.5	34
219	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet, The</i> , 2012, 380, 2018-2027.	6.3	759
220	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
221	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. <i>Lancet Oncology, The</i> , 2012, 13, 827-837.	5.1	240
222	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2012, 13, 983-992.	5.1	1,182
223	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology, The</i> , 2012, 13, 1210-1217.	5.1	254
224	Neoadjuvant Chemotherapy for Invasive Bladder Cancer. <i>Current Urology Reports</i> , 2012, 13, 136-146.	1.0	23
225	Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. <i>BJU International</i> , 2012, 109, 200-206.	1.3	29
226	Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. <i>European Urology</i> , 2012, 61, 11-25.	0.9	206
227	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	0.9	52
228	Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 950-960.	0.9	69
229	The Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 61, 1212-1221.	0.9	26
230	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. <i>BJU International</i> , 2012, 110, 1289-1300.	1.3	12
231	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	0.8	66
232	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736
233	Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Urology</i> , 2011, 77, 1166-1171.	0.5	84
234	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology, The</i> , 2011, 12, 211-214.	5.1	261

#	ARTICLE	IF	CITATIONS
235	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011, 21, 241-247.	0.9	12
236	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	0.9	119
237	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2011, 60, 270-278.	0.9	53
238	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. <i>European Urology</i> , 2011, 60, 279-290.	0.9	130
239	Sequelae of Treatment in Long-term Survivors of Testis Cancer. <i>European Urology</i> , 2011, 60, 516-526.	0.9	70
240	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	0.9	125
241	Pazopanib: Clinical development of a potent anti-angiogenic drug. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 163-171.	2.0	136
242	Sequential use of targeted agents in the treatment of renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 48-62.	2.0	53
243	Treatment of Patients With Metastatic Urothelial Cancer for Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2432-2438.	0.8	514
244	Neoadjuvant systemic therapy for urological malignancies. <i>BJU International</i> , 2010, 106, 6-22.	1.3	22
245	Novel Targeted therapy for advanced renal carcinoma: trials in progress. <i>Current Opinion in Urology</i> , 2010, 20, 382-387.	0.9	8
246	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 68-91.	2.0	105
247	Role of targeted therapy in the treatment of advanced prostate cancer. <i>BJU International</i> , 2010, 105, 748-767.	1.3	26
248	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. <i>BJU International</i> , 2010, 106, 462-469.	1.3	207
249	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. <i>International Journal of Urology</i> , 2010, 17, 228-240.	0.5	8
250	Is there a role for presurgical therapy for renal cell carcinoma?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 807-812.	1.1	1
251	Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2010, 70, 983-1000.	4.9	98
252	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology</i> , The, 2010, 11, 861-870.	5.1	123

#	ARTICLE	IF	CITATIONS
253	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology</i> , The, 2010, 11, 1066-1073.	5.1	830
254	Pazopanib in renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 232-3.	0.3	11
255	Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7421-7428.	3.2	203
256	Satraplatin for the therapy of castration-resistant prostate cancer. <i>Future Oncology</i> , 2009, 5, 931-940.	1.1	7
257	Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 5431-5438.	0.8	312
258	Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks. <i>European Urology</i> , 2009, 55, 62-75.	0.9	139
259	Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2009, 55, 348-358.	0.9	79
260	Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. <i>European Urology</i> , 2009, 56, 594-605.	0.9	174
261	Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. <i>European Urology</i> , 2009, 56, 959-971.	0.9	58
262	Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. <i>Cancer</i> , 2009, 115, 2652-2659.	2.0	83
263	Management of good risk germâ€cell tumours. <i>BJU International</i> , 2009, 104, 1387-1391.	1.3	4
264	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. <i>Update on Cancer Therapeutics</i> , 2009, 3, 133-145.	0.9	2
265	Optimizing outcomes at every stage of bladder cancer: Do we practice it?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 72-74.	0.8	16
266	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <i>European Urology Supplements</i> , 2009, 8, 738-746.	0.1	5
267	Advances in the Management of Metastatic Renal Cell Cancer. <i>European Urology Supplements</i> , 2009, 8, 758-761.	0.1	0
268	Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum. <i>European Urology Supplements</i> , 2009, 8, 733-737.	0.1	2
269	A new era in prostate cancer therapy: new targets and novel therapeutics. <i>Targeted Oncology</i> , 2008, 3, 31-39.	1.7	0
270	Novel agents for muscleâ€invasive and advanced urothelial cancer. <i>BJU International</i> , 2008, 101, 937-943.	1.3	11

#	ARTICLE	IF	CITATIONS
271	THE FUTURE OF PROSTATE CANCER. BJU International, 2008, 101, 934-936.	1.3	0
272	Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU International, 2008, 102, 1607-1609.	1.3	31
273	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU International, 2008, 102, 1354-1360.	1.3	15
274	Bladder Cancer Today. BJU International, 2008, 102, 1203-1203.	1.3	0
275	Differences in depressive thoughts between major depressive disorder, IFN- γ -induced depression, and depressive disorders among cancer patients. Journal of Psychosomatic Research, 2008, 65, 153-156.	1.2	15
276	Novel treatment options for refractory germ cell tumors. Update on Cancer Therapeutics, 2008, 3, 89-96.	0.9	0
277	Development of novel agents and combinations for renal carcinoma. Update on Cancer Therapeutics, 2008, 3, 97-103.	0.9	0
278	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 253-261.	1.9	84
279	Urologists and clinical trials. Nature Reviews Urology, 2008, 5, 229-229.	1.4	1
280	Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nature Reviews Urology, 2008, 5, 422-423.	1.4	2
281	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	0.8	127
282	Molecular pathways and the hope of targeting angiogenesis. Nature Reviews Urology, 2007, 4, 470-471.	1.4	1
283	Introduction: A multidisciplinary approach to genitourinary malignancy: does this topic warrant further debate?. Nature Reviews Urology, 2007, 4, S1-S2.	1.4	0
284	The evolving role of chemotherapy in advanced urothelial cancer. Current Opinion in Supportive and Palliative Care, 2007, 1, 180-186.	0.5	1
285	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	1.3	36
286	Signal-transduction inhibitors in renal cell carcinoma. BJU International, 2007, 99, 1289-1295.	1.3	12
287	Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU International, 2007, 100, 533-535.	1.3	3
288	Current Indications for Chemotherapy in Prostate Cancer Patients. European Urology, 2007, 51, 17-26.	0.9	66

#	ARTICLE	IF	CITATIONS
289	Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer to Enhance Survival and/or as a Strategy for Bladder Preservation. <i>Seminars in Oncology</i> , 2007, 34, 122-128.	0.8	14
290	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 176-185.	2.0	42
291	New treatment approaches in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2006, 16, 337-341.	0.9	17
292	Apples and oranges. <i>BJU International</i> , 2006, 97, 435-438.	1.3	11
293	Cancer and its Management. <i>BJU International</i> , 2006, 97, 651-651.	1.3	3
294	WHAT HAS BEEN LEARNED FROM META-ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER?. <i>BJU International</i> , 2006, 98, 487-489.	1.3	13
295	Current therapies and advances in the treatment of pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 231-241.	2.0	85
296	State-of-the-art management of metastatic disease at initial presentation or recurrence. <i>World Journal of Urology</i> , 2006, 24, 543-556.	1.2	14
297	Adjuvant bicalutamide for early prostate cancer: an update. <i>Nature Reviews Urology</i> , 2006, 3, 408-409.	1.4	0
298	Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. <i>Nature Reviews Urology</i> , 2005, 2, 20-21.	1.4	0
299	What's new in the treatment of metastatic kidney cancer?. <i>BJU International</i> , 2005, 95, 1171-1180.	1.3	13
300	Satraplatin in the treatment of hormone-refractory prostate cancer. <i>BJU International</i> , 2005, 96, 990-994.	1.3	30
301	Chemotherapy for local treatment of bladder cancer. <i>Seminars in Radiation Oncology</i> , 2005, 15, 60-65.	1.0	9
302	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 67-81.	2.0	24
303	Adjuvant chemotherapy for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 987-991.	1.1	3
304	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. <i>EAU Update Series</i> , 2003, 1, 108-117.	0.5	7
305	Numeric Definition of the Clinical Performance of the Nested Reverse Transcription-PCR for Detection of Hematogenous Epithelial Cells and Correction for Specific mRNA of Non-Target Cell Origin as Evaluated for Prostate Cancer Cells. <i>Clinical Chemistry</i> , 2003, 49, 1458-1466.	1.5	35
306	High-risk metastatic urothelial cancer: chances for cure?. <i>Current Opinion in Urology</i> , 2002, 12, 441-448.	0.9	20

#	ARTICLE	IF	CITATIONS
307	Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. <i>Urology</i> , 2002, 59, 227-231.	0.5	114
308	Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. <i>Lancet</i> , The, 2002, 360, 103-108.	6.3	1,617
309	Guidelines on Bladder Cancer. <i>European Urology</i> , 2002, 41, 105-112.	0.9	370
310	Localized and locally advanced bladder cancer. <i>Current Treatment Options in Oncology</i> , 2002, 3, 413-428.	1.3	6
311	New drugs and new approaches for the treatment of metastatic urothelial cancer. <i>World Journal of Urology</i> , 2002, 20, 158-166.	1.2	34
312	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 89-106.	2.0	32
313	Highlights of contemporary issues in the medical management of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 105-121.	2.0	17
314	Overview of international collaborative group prostate cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 153-158.	2.0	3
315	Differences in Gene Expression in Muscle– Invasive Bladder Cancer: A Comparison of Italian and American Patients. <i>European Urology</i> , 2001, 39, 430-437.	0.9	9
316	Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. <i>Current Opinion in Urology</i> , 2001, 11, 523-529.	0.9	14
317	Neo-adjuvant chemotherapy in invasive bladder cancer. <i>World Journal of Urology</i> , 2001, 19, 94-98.	1.2	16
318	Second-Line Chemotherapy in Advanced Bladder Cancer. <i>Urologia Internationalis</i> , 2000, 64, 61-69.	0.6	6
319	A critical review of the management of bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 193-207.	2.0	10
320	Comparison of the BTA <i>stat</i> TM Test with Voided Urine Cytology and Bladder Wash Cytology in the Diagnosis and Monitoring of Bladder Cancer. <i>European Urology</i> , 1999, 35, 52-56.	0.9	113
321	THE MANAGEMENT OF STAGE I TESTIS CANCER. <i>Urologic Clinics of North America</i> , 1998, 25, 435-449.	0.8	48
322	Muscle–invasive transitional cell carcinoma of the bladder: strategies for bladder preservation. <i>Current Opinion in Urology</i> , 1998, 8, 431-435.	0.9	1
323	Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin. <i>New England Journal of Medicine</i> , 1997, 337, 295-300.	13.9	1,455
324	Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1997, 3, 133-140.	0.8	2

#	ARTICLE	IF	CITATIONS
325	Hormone refractory prostate cancer. <i>Current Opinion in Urology</i> , 1996, 6, 258-264.	0.9	0
326	Multimodal therapy of advanced bladder cancer. <i>Current Opinion in Urology</i> , 1995, 5, 260-266.	0.9	1
327	Bladder Preservation—a Prospect for Patients with Urinary Bladder Cancer. <i>Acta Oncologica</i> , 1995, 34, 589-597.	0.8	5
328	Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995, 1, 127-133.	0.8	13
329	Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 1995, 35, 123-128.	0.3	9
330	Neoadjuvant m-vac (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. <i>Cancer</i> , 1993, 72, 1975-1982.	2.0	60
331	Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. <i>Cancer</i> , 1991, 67, 1525-1531.	2.0	131
332	Transurethral resection of the prostate and metastatic prostate cancer. <i>Cancer</i> , 1991, 68, 1895-1898.	2.0	20
333	Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. <i>Cancer</i> , 1991, 68, 2561-2565.	2.0	85
334	Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990, 8, 391-2.	1.2	17
335	Neo-adjuvant Chemotherapy for Invasive Bladder Cancer. Experience with the M-VAC Regimen. <i>British Journal of Urology</i> , 1989, 64, 250-256.	0.1	109
336	Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. <i>Cancer</i> , 1989, 64, 2448-2458.	2.0	654
337	Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 753-754.	0.9	9
338	Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium. <i>New England Journal of Medicine</i> , 1988, 318, 1414-1422.	13.9	962
339	Etoposide (VP-16) in the Treatment of Advanced Adenocarcinoma of the Pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988, 11, 172-173.	0.6	7
340	Phase II Trial of Menogarol in the Treatment of Advanced Adenocarcinoma of the Pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988, 11, 174-176.	0.6	4
341	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Extravesical Urinary Tract Tumors. <i>Journal of Urology</i> , 1988, 139, 475-477.	0.2	48
342	Evaluation of New Anticancer Agents Against Human Pancreatic Carcinomas in Nude Mice. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987, 10, 219-221.	0.6	13

#	ARTICLE	IF	CITATIONS
343	Phase II trial of 10 deaza-aminopterin in patients with bladder cancer. <i>Investigational New Drugs</i> , 1986, 4, 171-4.	1.2	4
344	Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 24-26.	1.1	21
345	Phase I/II trial of intravesical methotrexate for superficial bladder tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 265-269.	1.1	3
346	Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium. <i>Journal of Urology</i> , 1985, 133, 403-407.	0.2	630
347	Phase II trial of 1,2-diaminocyclohexane-(4-carboxyphth-alato) platinum(II) (DACCP) in colorectal carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 503-506.	0.6	2
348	MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 529-534.	0.6	3
349	Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methane-sulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1983, 6, 459-462.	0.6	6
350	Fine flutterings of the aortic valve as demonstrated by aortic valve echocardiograms. <i>American Heart Journal</i> , 1978, 95, 807-808.	1.2	17